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Background: Tiotropium, a long-acting anticholinergic bronchodilator, has demonstrated efﬁcacy and
safety as add-on therapy to inhaled corticosteroids (ICS), with or without other maintenance therapies, in
patients with symptomatic asthma.
Objective: To evaluate safety and tolerability of tiotropium delivered via the Respimat® device, compared
with placebo, each as add-on to at least ICS therapy, in a pooled sample of adults with symptomatic
asthma at different treatment steps.
Methods: Data were pooled from seven Phase II and III, randomised, double-blind, parallel-group trials of
12e52 weeks’ treatment duration, which investigated once-daily tiotropium Respimat® (5 mg, 2.5 mg)
versus placebo as add-on to different background maintenance therapy including at least ICS. Adverse
events (AEs) including serious AEs were assessed throughout treatment þ 30 days after the last dose of
trial medication.
Results: Of 3474 patients analysed, 2157 received tiotropium. The percentage of patients with AEs was
comparable between treatment groups: tiotropium 5 mg, 60.8%; placebo 5 mg pool, 62.5%; tiotropium
2.5 mg, 57.1%; placebo 2.5 mg pool, 55.1%. Consistent with the disease proﬁle, the most frequent AEs
overall were asthma, decreased peak expiratory ﬂow rate (both less frequent with tiotropium) and
nasopharyngitis. Overall incidence of dry mouth, commonly associated with use of anticholinergics, was
low: tiotropium 5 mg, 1.0%; placebo 5 mg pool, 0.5%; tiotropium 2.5 mg, 0.4%; placebo 2.5 mg pool, 0.5%. The
percentage of cardiac disorder AEs was comparable between tiotropium and placebo: tiotropium 5 mg,
1.4%; placebo 5 mg pool, 1.4%; tiotropium 2.5 mg, 1.4%; placebo 2.5 mg pool, 1.1%. The proportions of
patients with serious AEs were balanced across groups: tiotropium 5 mg, 4.0%; placebo 5 mg pool, 4.9%;
tiotropium 2.5 mg, 2.0%; placebo 2.5 mg pool, 3.3%.
Conclusion: Tiotropium Respimat® demonstrated safety and tolerability comparable with those of
placebo, as add-on to at least ICS therapy, at different treatment steps in adults with symptomatic
asthma.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Asthma affects approximately 300 million people worldwide; it
is a heterogeneous condition with various underlying disease
processes and is usually characterised by chronic airway
inﬂammation [1]. The Global Initiative for Asthma recommends a
stepwise approach to achieving and maintaining control of asthma
symptoms [1]. Despite treatment according to current
recommendations, at least 40% of patients with asthma remain
symptomatic [2e4]. There is therefore a need for additional
treatment options.
A large and comprehensive Phase II and III clinical trial
programme, performed in more than 5000 adult patients with
symptomatic asthma, has investigated tiotropium delivered by the
Respimat® Soft Mist™ inhaler (Boehringer Ingelheim Pharma
GmbH & Co. KG, Ingelheim am Rhein, Germany) as add-on therapy
to inhaled corticosteroids (ICS) with or without other maintenance
therapies. This programme has conﬁrmed that tiotropium
Respimat® (hereafter referred to as ‘tiotropium’) is an efﬁcacious
add-on therapy, with safety and tolerability comparable with those
of placebo, across treatment steps [5e13]. Based on the published
evidence from the above programme, the 5 mg dose was approved
for use in the European Union in 2014 as add-on therapy to
maintenance ICS (800 mg budesonide or equivalent) plus a
long-acting b2-agonist (LABA), in patients aged 18 years who
experienced 1 severe asthma exacerbations in the previous year.
The 2015 update of the Global Initiative for Asthma guidelines
included tiotropium, delivered by the Respimat® inhaler, as an
add-on therapy option at steps 4 and 5 in patients aged 18 years
with a history of exacerbations [1]. The 2.5 mg tiotropium
Respimat® dose has since been approved by the US Food and Drug
Administration for once-daily maintenance treatment of asthma in
patients aged12 years; other countries that have approval include
Australia, Canada and Japan.
In addition to the safety reports of tiotropium add-on therapy in
individual clinical trials, an in-depth assessment of safety and
tolerability in a much larger patient sample can provide greater
power to detect any as yet unidentiﬁed safety signals. The objective
of the analysis described here was to evaluate the safety and
tolerability of once-daily tiotropium 5 mg and 2.5 mg (two puffs,
irrespective of dose) compared with placebo, each as add-on to at
least ICS therapy, in a large sample of adult patients with symp-
tomatic asthma at different treatment steps. To achieve this, data
were pooled across seven Phase II and III parallel-group trials of
tiotropium of 12e52 weeks’ duration.
2. Methods
2.1. Study design
The pooled analysis included all parallel-group Phase II or III
adult studies in the Boehringer Ingelheim programme of
tiotropium Respimat® in asthma. Studies of tiotropium Handi-
Haler® were not included. All trials were of randomised, double-
blind, placebo-controlled design of at least 12 weeks’ duration, in
adult patients (aged 18e75 years) with symptomatic asthma.
Tiotropium or placebo were each administered as add-on therapy
to ICS maintenance treatment with or without other background
therapies. Placebowas therefore equivalent to patients’ background
maintenance therapy.
Seventrialswereincludedinthispooledsafetyanalysis(Table1).One
ofthesewasaPhaseII,16-weektrialoftiotropium5mgandtwice-daily
salmeterol 50 mg in patients receiving ICS (study 205.342;
NCT00350207)[6].TheremainderwerePhaseIIIstudies:one12-week
trialoftiotropium5mgand2.5mginpatientsreceivingICS(GraziaTinA-asthma®:NCT01316380)[12];tworeplicate24-weektrialsofonce-daily
tiotropium5mgand2.5mgandtwice-dailysalmeterol50mginpatients
receiving ICS (MezzoTinA-asthma®: NCT01172808/NCT01172821)
[10]; two replicate 48-week trials of once-daily tiotropium 5 mg in
patients receiving ICS plus a LABA (PrimoTinA-asthma®:
NCT00772538/NCT00776984)[9];andone52-weektrialoftiotropium
5 mg and 2.5 mg in patients receiving ICS with or without a LABA(Ca-
denTinA-asthma®:NCT01340209) [11]. Furtherdetails regarding the
backgroundtherapy,treatmentarmsandprimaryendpointsofeachtrial
areprovidedinTable1;inclusionandexclusioncriteriaareprovidedin
Table2.
2.2. Analysis population
In all seven trials, patients were lifelong non-smokers or
ex-smokers (<10 pack-years) with no smoking for at least 1 year
before study entry. Patients with chronic obstructive pulmonary
disease (COPD), a signiﬁcant lung disease other than asthma or a
recent history of certain cardiac diseases (myocardial infarction;
hospitalisation for cardiac failure; unstable or life-threatening
cardiac arrhythmia; or cardiac arrhythmia requiring intervention
or a change in drug therapy) were excluded (Table 2).
In all the Phase III trials, patients were required to have symp-
tomatic asthma (as deﬁned by a seven-question Asthma Control
Questionnairemean score of1.5) and a diagnosis of asthma before
the age of 40 years. Patients were required to have bronchodilator
reversibility resulting in a forced expiratory volume in 1 s (FEV1)
increase of 12% and 200 mL (15e30 min after 400 mg salbuta-
mol), except in PrimoTinA-asthma® where patients were required
to have a positive hyper-responsiveness test or a positive trial of
glucocorticosteroids or bronchodilator reversibility deﬁned as
either an FEV1 increase of 12% and 200 mL or a peak expiratory
ﬂow increase of 20% after use of salbutamol/albuterol from a
pressurised metered-dose inhaler. Different degrees of lung func-
tion impairment were speciﬁed in the different trial protocols
(Table 2). A documented history of asthma of5 years was required
in the PrimoTinA-asthma® trials, and3months in theMezzoTinA-
asthma®, GraziaTinA-asthma® and CadenTinA-asthma® trials
[9e12].
The treatment history (treatment step on enrolment) speciﬁed
in each trial differed and reﬂected the severity of the patient pop-
ulation (Table 2). Background treatment was required to be stable
for 4 weeks before enrolment, as follows: PrimoTinA-asthma®:
ICS (800 mg budesonide or equivalent) plus a LABA; MezzoTinA-
asthma®: ICS (400e800 mg budesonide or equivalent) alone or in
ﬁxed combination with a LABA or short-acting b2-agonist (SABA);
GraziaTinA-asthma®: ICS (200e400 mg budesonide or equivalent)
alone or in ﬁxed combination with a SABA; CadenTinA-asthma®:
ICS (400e800 mg budesonide or equivalent) alone or in ﬁxed
combination with a LABA.
In the Phase II study 205.342, patients were required to be
homozygous for arginine at the 16th amino acid position of the
b2-adrenergic receptor and to have a documented history of
asthma and bronchodilator reversibility resulting in an FEV1 in-
crease of 12% and 200 mL (30 min after 400 mg salbutamol
and 80 mg ipratropium). Patients also received stable treatment
with ICS (400e1000 mg budesonide or equivalent) alone or in
ﬁxed combination with a LABA or SABA for 3 weeks before
enrolment [6].
2.3. Trial medication
During the treatment period, all trials investigated tiotropiumand
placebo, delivered by the Respimat inhaler®, each as add-on therapy
to pre-trialmaintenance ICS (with a LABA inPrimoTinA-asthma®, and
Table 1
Summary of study designs for the Phase II and III trials included in the pooled safety analysis.
Authors; study identiﬁcation
number; study number/name
Phase Baseline
maintenance
therapy
Duration of
treatment
(weeks)
na Randomisation Treatment arms, as add-on to
baseline maintenance therapy
Primary end pointsb
Bateman et al., 2011 [6]
NCT00350207
Study 205.342
II ICS (400e1000 mg
budesonide or
equivalent per day)
16 388 1:1:1 Once-daily tiotropium Respimat®
5 mg (n ¼ 128);
twice-daily salmeterol 50 mg
(n ¼ 134);
placebo Respimat® (n ¼ 126)
Mean weekly morning PEF
response at Week 16
Paggiaro et al., 2016 [12]
NCT01316380
GraziaTinA-asthma®
III ICS (200e400 mg
budesonide or
equivalent per day)
12 464 1:1:1 Once-daily tiotropium Respimat®
5 mg (n ¼ 155);
once-daily tiotropium Respimat®
2.5 mg (n ¼ 154);
placebo Respimat® (n ¼ 155)
Peak FEV1(0e3h) response at
Week 12
Kerstjens et al., 2015 [10]
NCT01172808
NCT01172821
MezzoTinA-asthma®
III ICS (400e800 mg
budesonide or
equivalent per day)
24 2100 1:1:1:1 Once-daily tiotropium Respimat®
5 mg (n ¼ 517);
once-daily tiotropium Respimat®
2.5 mg (n ¼ 519);
twice-daily salmeterol 50 mg
(n ¼ 541);
placebo (n ¼ 523)
Co-primary end points: peak
FEV1(0e3h) and trough FEV1
responses and ACQ-7 responder
rate (pooled) at Week 24
Kerstjens et al., 2012 [9]
NCT00772538
NCT00776984
PrimoTinA-asthma®
III ICS (800 mg
budesonide or
equivalent per
day) þ LABA
48 912 1:1 Once-daily tiotropium Respimat®
5 mg (n ¼ 456);
placebo Respimat® (n ¼ 456)
Co-primary end points: peak
FEV1(0e3h) and trough FEV1
responses at Week 24, and time
to ﬁrst severe asthma
exacerbation during the 48-
week treatment period
(pooled)
Ohta et al., 2015 [11]
NCT01340209
CadenTinA-asthma®
III ICS (400e800 mg
budesonide or
equivalent per
day) ± LABA
52 285 2:2:1 Once-daily tiotropium Respimat®
5 mg (n ¼ 114);
once-daily tiotropium Respimat®
2.5 mg (n ¼ 114);
placebo Respimat® (n ¼ 57)
Primary objective: to evaluate
long-term safety; therefore, no
primary efﬁcacy end points
were deﬁned
Secondary efﬁcacy end points
included trough FEV1 and
trough FVC responses, in-clinic
trough PEF rate response and
ACQ-7 responder rate
ACQ-7¼ seven-question Asthma Control Questionnaire. FEV1¼ forced expiratory volume in 1 s. FVC¼ forced vital capacity; ICS¼ inhaled corticosteroids. LABA ¼ long-acting
b2-agonist. Peak FEV1(0e3h) ¼ peak forced expiratory volume in 1 s within 3 h post-dose. PEF ¼ peak expiratory ﬂow.
a Treated set.
b Response deﬁned as change from baseline at study end point.
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MezzoTinA-asthma® and study 205.342, patients were to be on
medium-dose ICS (400e800 mg and 400e1000 mg budesonide or
equivalent, respectively). An additional placebo in MezzoTinA-
asthma® and study 205.342 was a hydroﬂuoroalkane metered-dose
inhaler, to match the salmeterol pressurised metered-dose inhaler
arm in these studies. In GraziaTinA-asthma®, patients were to be on
low-dose ICS (200e400 mg budesonide or equivalent). Salbutamol
was allowed as rescue medication as necessary during each of the
seven studies; a washout period of 8 h was required before lung
function tests.
2.4. End points
A descriptive assessment of safety over 52 weeks was the
primary objective in CadenTinA-asthma®. Safety was a secondary
end point in all other trials.
All adverse events (AEs), including serious AEs (SAEs), occurring
during the clinical trials (ie from signing informed consent until 30
days after the last dose of trial medication) were collected, docu-
mented and reported to the sponsor by the investigator on the
appropriate reporting forms. All events with an onset after the ﬁrst
dose of trial medication up to 30 days after the last dose of trial
medication were assigned to the treatment period; others were
assigned to either the screening period or the post-trial period, as
appropriate. AEs were coded using the Medical Dictionary for
Regulatory Activities (version 16.1). For each AE, the investigatorwas to provide the onset and end dates, intensity, treatment
required, outcome, seriousness and action taken with the investi-
gational drug, and to determine the relationship of the investiga-
tional drug to the AE. All AEs were followed up until resolved or
sufﬁciently characterised.
Standard deﬁnitions of AEs and SAEs were applied. An AE was
deﬁned as any untoward medical occurrence, including an exac-
erbation of a pre-existing condition, in a patient who received the
trial medication; the event did not necessarily have a causal rela-
tionship with the trial medication. An SAE was deﬁned as any AE
which: resulted in death; was immediately life-threatening;
resulted in persistent or signiﬁcant disability or incapacity;
required or prolonged patient hospitalisation; was a congenital
anomaly or birth defect; or was to be deemed serious for any other
reason, if it was an important medical event when based on
appropriate medical judgement, which may have jeopardised the
patient and required medical or surgical intervention to prevent
one of the outcomes listed above. A treatment-related AE was
deﬁned as an AE for which there was a reasonable causal rela-
tionship between the randomised trial medication (tiotropium or
placebo) and the AE. Themedical judgement of the investigator was
used to determine the causal relationship, considering all relevant
factors such as the temporal relationship between treatment
administration and the AE, and confounding factors such as
concomitant medication and concomitant diseases.
Laboratory parameters, vital signs and a 12-lead electrocardio-
gram were recorded in the individual studies; these assessments
Table 2
Main inclusion and exclusion criteria for all included trials.
Authors; study
identiﬁcation number;
study number/name
Bateman et al., 2011 [6]
NCT00350207
Study 205.342
Paggiaro et al., 2016
[12]
NCT01316380
GraziaTinA-asthma®
Kerstjens et al., 2015
[10]
NCT01172808
NCT01172821
MezzoTinA-asthma®
Kerstjens et al., 2012
[9]
NCT00772538
NCT00776984
PrimoTinA-asthma®
Ohta et al., 2015 [11]
NCT01340209
CadenTinA-asthma®
Population 18e65 years of age;
homozygous for B16-
Arg
18e75 years of age 18e75 years of age 18e75 years of age 18e75 years of age
Severity of persistent
asthma
Moderate Mild Moderate Severe, 1
exacerbations in the
past year
Moderate to severe
History of asthma Yes, duration not
deﬁned
3 months 3 months 5 years 12 weeks
Symptomatic asthma Not deﬁned ACQ 1.5a ACQ 1.5a ACQ 1.5a ACQ 1.5a
Minimum asthma
controller
medication
ICS (400e1000 mg
budesonide or
equivalent)b
ICS (200e400 mg
budesonide or
equivalent)c
ICS (400e800 mg
budesonide or
equivalent)b
ICS (800 mg
budesonide or
equivalent) þ LABA
ICS (400e800 mg
budesonide or
equivalent) ± LABA
FEV1 % predicted at
screening
Pre-bronchodilator: On
LABA: 90%
Not on LABA: 80%
Pre-bronchodilator: 60e90% Post-bronchodilator:
80%, FEV1/FVC 70%
Pre-bronchodilator: 60
e90%
Reversibility at
screening
Yesd Yese Yese Not requiredf Yese
Smoking history Lifelong non-smoker or ex-smoker (<10 pack-years) with no smoking for at least 1 year before study entry
Exclusion criteria Chronic obstructive pulmonary disease or signiﬁcant lung disease other than asthma
Recent history (within the past 6 months) of myocardial infarction; hospitalised for cardiac failure during past year; unstable or life-
threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within past year
ACQ ¼ Asthma Control Questionnaire. FEV1 ¼ forced expiratory volume in 1 s. FVC ¼ forced vital capacity; ICS ¼ inhaled corticosteroids. LABA ¼ long-acting b2-agonist.
SABA ¼ short-acting b2-agonist.
a At screening (Visit 1) and randomisation (Visit 2).
b Alone or in a ﬁxed combination with a LABA or a SABA.
c Alone or in a ﬁxed combination with a SABA.
d An FEV1 increase of 12% and 200 mL either 45 min after 80 mg ipratropium or 30 min after subsequent inhalation of 400 mg salbutamol.
e An FEV1 increase of 12% and 200 mL 15e30 min after 400 mg salbutamol/albuterol.
f Used for patient characterisation only.
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also recorded as AEs. In all trials, patients with known moderate or
severe renal impairment (deﬁned as creatinine clearance 50 mL/
min) were monitored closely but were not excluded.
2.5. Statistical analyses
Analyses of safety data were based on the treated set, deﬁned as
all randomised patients who received at least one dose of trial
medication, and were evaluated using descriptive analyses. No
inferential statistical analyses of safety outcomes were
pre-speciﬁed.
All seven trials except CadenTinA-asthma® were powered for
analyses of efﬁcacy end points. The primary objective of Caden-
TinA-asthma® was to descriptively evaluate the safety of
tiotropium 5 mg and 2.5 mg; the study was not powered to detect a
difference in safety proﬁle between either tiotropium dose and
placebo, but to numerically compare the incidence of speciﬁc AEs
and AEs overall.
The tiotropium 5 mg dose was assessed in seven trials, and the
2.5 mg dose in four trials. All seven trials included in the analysis
included a tiotropium 5 mg arm, but only four included a
tiotropium 2.5 mg arm. Thus, when comparing the pooled
tiotropium 2.5 mg data set with that of placebo, it is not accurate to
compare it with the pooled placebo arms from all seven trials.
Therefore, we present two placebo groups: a placebo 5 mg pool for
comparison with tiotropium 5 mg (placebo patients pooled from all
seven trials) and a placebo 2.5 mg pool for comparison with
tiotropium 2.5 mg (placebo patients pooled from the four trials that
included a tiotropium 2.5 mg arm: MezzoTinA-asthma® [two
replicate trials], GraziaTinA-asthma® and CadenTinA-asthma®). In
this analysis, which is focused only on tiotropium compared withplacebo, we do not report data from the salmeterol arms of study
205.342 or MezzoTinA-asthma® [6,10].
3. Results
In this pooled analysis of seven randomised, placebo-controlled,
parallel-group trials in adult patients with symptomatic asthma,
data from 1370 patients who received tiotropium 5 mg and 1317
patients who received placebo were compared (tiotropium 5 mg
pool), as were data from 787 patients receiving tiotropium 2.5 mg
and 735 patients receiving placebo (tiotropium 2.5 mg pool).
3.1. Baseline demographics and disease characteristics
Baseline patient demographics and disease characteristics in
both pools were similar between tiotropium and placebo groups
(Table 3). All patients were adults: the mean age (± standard
deviation [SD]) in each treatment group ranged from 43.2 (12.9)
to 46.9 (13.5) years. Approximately 60% of patients were female
and the majority were white or Asian. Most patients had never
smoked (77.2e84.5%), and the mean duration of asthma (± SD)
ranged from 20.3 (13.6) to 23.8 (14.7) years.
Comparison between the 5 mg and 2.5 mg pools was not an
objective of this analysis. The differences in baseline characteristics
between the 5 mg and 2.5 mg pools reﬂect the differences in inclu-
sion criteria of the trials included in each pool; there was
comparatively less severe disease in the 2.5 mg pool. Study 205.342
and PrimoTinA-asthma® included patients at higher treatment
steps than in the other trials, and contained no tiotropium 2.5 mg
arm (Table 3). Consequently, baseline values for lung function were
higher andmean dose of ICS was lower in the 2.5 mg pool versus the
5 mg pool.
Table 3
Baseline patient demographics and disease characteristics in the pooled safety analysis.
Tiotropium Respimat®
5 mg pool (N ¼ 1370)
Placebo Respimat® (tiotropium
Respimat® 5 mg pool)a (N ¼ 1317)
Tiotropium Respimat®
2.5 mg pool (N ¼ 787)
Placebo Respimat® (tiotropium
Respimat® 2.5 mg pool)a (N ¼ 735)
Female, n (%) 817 (59.6) 805 (61.1) 470 (59.7) 452 (61.5)
Race, n (%)
White 857 (62.6) 864 (65.6) 374 (47.5) 365 (49.7)
Asian 427 (31.2) 357 (27.1) 360 (45.7) 306 (41.6)
Black/African-American 50 (3.6) 59 (4.5) 17 (2.2) 28 (3.8)
American Indian/Alaska Native 35 (2.6) 35 (2.7) 34 (4.3) 35 (4.8)
Hawaiian/Paciﬁc Isle 1 (0.1) 2 (0.2) 2 (0.3) 1 (0.1)
Ethnicity, n (%)b
Not Hispanic/Latino 1045 (76.3) 1054 (80.0) 602 (76.5) 613 (83.4)
Hispanic/Latino 83 (6.1) 80 (6.1) 71 (9.0) 65 (8.8)
Age, mean ± SD 46.5 ± 13.3 46.9 ± 13.5 43.7 ± 13.0 43.2 ± 12.9
Age group, n (%)
<65 years 1250 (91.2) 1186 (90.1) 746 (94.8) 699 (95.1)
65 years 120 (8.8) 131 (9.9) 41 (5.2) 36 (4.9)
BMI, mean ± SD 27.3 ± 5.9 27.3 ± 6.0 26.3 ± 5.9 26.6 ± 6.0
Smoking status, n (%)
Never smoked 1058 (77.2) 1060 (80.5) 656 (83.4) 621 (84.5)
Ex-smoker 312 (22.8) 256 (19.4) 131 (16.6) 113 (15.4)
Current smoker 0 1 (0.1) 0 1 (0.1)
Smoking history, mean pack-
years ± SD
4.81 ± 2.9 4.74 ± 2.9 4.08 ± 2.8 4.64 ± 3.0
B16-Arg/Arg genotype, n (%) 171 (12.5) 164 (12.5) NA NA
Duration of asthma, mean
years ± SD
23.7 ± 14.5 23.8 ± 14.7 21.1 ± 14.2 20.3 ± 13.6
Patients with cardiac history,
n (%)c
27 (2.0) 31 (2.4) 11 (1.4) 8 (1.1)
Concomitant allergic rhinitis,
n (%)
381 (27.8) 366 (27.8) 275 (34.9) 250 (34.0)
Concomitant therapies at baseline, n (%)
LTRAs 166 (12.1) 166 (12.6) 84 (10.7) 58 (7.9)
LABAs 512 (37.4) 488 (37.1) 62 (7.9) 36 (4.9)
ICS dose of stable maintenance
therapy, mg, mean ± SD
841.7 ± 466.7 834.0 ± 472.0 640.3 ± 288.8 619.8 ± 248.7
FEV1 % predicted at screening,
pre-bronchodilator
66.4 ± 13.4 66.4 ± 13.7 73.0 ± 8.4 73.3 ± 8.4
FEV1 % predicted at screening,
post-bronchodilator
79.4 ± 17.8 79.5 ± 17.6 90.0 ± 11.5 89.8 ± 10.8
FEV1 % reversibility, mean ± SD 19.9 ± 13.5 20.1 ± 13.7 23.6 ± 11.7 22.8 ± 10.4
Allergic/inﬂammatory asthma, n (%)
Clinician judgement ‘yes’ 796 (58.1) 770 (58.5) 526 (66.8) 487 (66.3)
Total serum IgE >430 mg/L 679 (49.6) 627 (47.6) 470 (59.7) 443 (60.3)
Blood eosinophil count
>0.6  109/L
281 (20.5) 262 (19.9) 170 (21.6) 154 (21.0)
Treated set.
B16-Arg/Arg ¼ homozygous for arginine at the 16th amino acid position of the b2-adrenergic receptor. BMI ¼ body mass index. FEV1 ¼ forced expiratory volume in 1 s.
ICS ¼ inhaled corticosteroids. IgE ¼ immunoglobulin E. LABA ¼ long-acting b2-agonist. LTRA ¼ leukotriene receptor antagonist. NA ¼ not applicable. SD ¼ standard deviation.
a Placebo Respimat® 5 mg pool: all seven trials; placebo Respimat® 2.5 mg pool: MezzoTinA-asthma®, GraziaTinA-asthma® and CadenTinA-asthma®.
b Ethnicity missing for patients in study 205.342 because it was not collected on the case report form.
c A patient with cardiac history was deﬁned as a patient who responded ‘yes’ to at least one of the following medical histories: myocardial infarction; cerebrovascular
accidents; cardiac arrhythmia; or heart failure New York Heart Association class III or IV.
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Mean (± SD) exposure to trial medicationwas 217.2 (105.9) days
in the tiotropium 5 mg pool versus 211.4 (103.2) days in corre-
sponding placebo, and 177.3 (84.2) days in the tiotropium 2.5 mg
pool versus 162.1 (68.8) days in corresponding placebo. The varia-
tion in treatment exposure between pools is due to the marked
differences in mean treatment exposure between trials of different
duration. Within each trial, mean exposure was comparable
between treatment arms (Supplementary Table 1).
3.3. Safety
3.3.1. AEs, treatment-related AEs and SAEs
The frequency of patients reporting any type of AE was com-
parable between the tiotropium 5 mg pool (n ¼ 833, 60.8%) and
corresponding placebo pool (n ¼ 823, 62.5%), and between thetiotropium 2.5 mg pool (n ¼ 449, 57.1%) and corresponding placebo
pool (n ¼ 405, 55.1%) (Table 4). Treatment-related AEs were re-
ported in a similar percentage of patients between the tiotropium
5 mg pool and corresponding placebo pool, and between the tio-
tropium 2.5 mg pool and corresponding placebo pool (Table 4). The
distribution of patients with AEs leading to discontinuation of trial
medication was balanced between active treatment and placebo
groups, in both the 5 mg and 2.5 mg pools (Table 4): tiotropium 5 mg
(n¼ 25, 1.8%); placebo 5 mg (n¼ 30, 2.3%); tiotropium 2.5 mg (n¼ 9,
1.1%); placebo 2.5 mg (n ¼ 14, 1.9%).
The most commonly reported AEs, occurring in 2% of patients
in any treatment group, are presented in Table 5. Asthma wors-
ening/exacerbation, decreased peak expiratory ﬂow rate and upper
respiratory tract infection occurred less frequently with tiotropium
compared with placebo, in both the 5 mg and 2.5 mg pools.
Commonly reported AEs occurring more frequently with
tiotropium comparedwith placebo in both the 5 mg and 2.5 mg pools
Table 4
Overall summary of adverse events in the pooled safety analysis.
n (%) Tiotropium Respimat®
5 mg pool (N ¼ 1370)
Placebo Respimat® (tiotropium
Respimat® 5 mg pool)a (N ¼ 1317)
Tiotropium Respimat®
2.5 mg pool (N ¼ 787)
Placebo Respimat® (tiotropium
Respimat® 2.5 mg pool)a (N ¼ 735)
Patients with any AE 833 (60.8) 823 (62.5) 449 (57.1) 405 (55.1)
Patients with investigator-deﬁned
treatment-related AEs
82 (6.0) 58 (4.4) 44 (5.6) 33 (4.5)
Patients with AEs leading to
discontinuation of trial
medication
25 (1.8) 30 (2.3) 9 (1.1) 14 (1.9)
Patients with serious AEsb 55 (4.0) 65 (4.9) 16 (2.0) 24 (3.3)
Fatal 0 0 0 0
Immediately life-threatening 5 (0.4) 1 (0.1) 1 (0.1) 1 (0.1)
Disabling/incapacitating 2 (0.1) 0 0 0
Requiring hospitalisation 50 (3.6) 60 (4.6) 16 (2.0) 20 (2.7)
Prolonged hospitalisation 3 (0.2) 3 (0.2) 1 (0.1) 2 (0.3)
Other 6 (0.4) 3 (0.2) 0 3 (0.4)
Treated set.
AE ¼ adverse event.
a Placebo Respimat® 5 mg pool: all seven trials; placebo Respimat® 2.5 mg pool: MezzoTinA-asthma®, GraziaTinA-asthma® and CadenTinA-asthma®.
b A patient may be counted in more than one seriousness criterion. Percentages calculated using total number of patients per treatment as the denominator.
Table 5
Adverse events occurring in 2% of patients in any treatment group (by preferred term).
n (%) Tiotropium Respimat® 5 mg
pool (N ¼ 1370)
Placebo Respimat® (tiotropium Respimat®
5 mg pool)a (N ¼ 1317)
Tiotropium Respimat® 2.5 mg
pool (N ¼ 787)
Placebo Respimat® (tiotropium Respimat®
2.5 mg pool)a (N ¼ 735)
Asthmab 359 (26.2) 406 (30.8) 140 (17.8) 157 (21.4)
Decreased peak
expiratory ﬂow rate
176 (12.8) 219 (16.6) 67 (8.5) 97 (13.2)
Nasopharyngitis 153 (11.2) 142 (10.8) 102 (13.0) 77 (10.5)
Upper respiratory tract
infection
54 (3.9) 69 (5.2) 37 (4.7) 50 (6.8)
Headache 45 (3.3) 50 (3.8) 26 (3.3) 15 (2.0)
Bronchitis 54 (3.9) 31 (2.4) 24 (3.0) 10 (1.4)
Sinusitis 35 (2.6) 34 (2.6) 20 (2.5) 8 (1.1)
Inﬂuenza 34 (2.5) 27 (2.1) 8 (1.0) 10 (1.4)
Pharyngitis 28 (2.0) 17 (1.3) 26 (3.3) 10 (1.4)
Treated set.
a Placebo Respimat® 5 mg pool: all seven trials; placebo Respimat® 2.5 mg pool: MezzoTinA-asthma®, GraziaTinA-asthma® and CadenTinA-asthma®.
b Represents asthma worsening or exacerbation.
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bronchitis led to treatment discontinuation, in two patients in the
tiotropium 5 mg pool (0.1%).
Treatment-related AEs reported in 0.3% of patients in any
treatment group are presented in Table 6. The most common
treatment-related AEs in the 5 mg pool were asthma, dry mouth,
dysphonia and thirst, and in the 2.5 mg pool, asthma, cough, dry
mouth, headache and thirst. Treatment-related AEs occurring with
greater frequency with tiotropium versus placebo included
dysphonia, dry throat, dry mouth, thirst, headache and palpitations
in the 5 mg pool, and oropharyngeal discomfort, nausea, headache,
elevated gamma-glutamyltransferase and palpitations in the 2.5 mg
pool. The largest difference in frequency of treatment-related AEs
between tiotropium and placebo was 0.5% points.
The frequency of patients reporting SAEs was comparable
between treatment groups in each pool: tiotropium 5 mg (n ¼ 55,
4.0%); placebo 5 mg (n ¼ 65, 4.9%); tiotropium 2.5 mg (n ¼ 16, 2.0%);
placebo 2.5 mg (n ¼ 24, 3.3%) (Table 7). The most common SAE was
asthma worsening/exacerbation, which was reported at a similar
frequencywith tiotropium and placebo in each pool: tiotropium5 mg
(n ¼ 19, 1.4%); placebo 5 mg (n ¼ 27, 2.1%); tiotropium 2.5 mg (n ¼ 2,
0.3%); placebo 2.5 mg (n ¼ 5, 0.7%). Drug-related SAEs occurred in
two patients: one patient in the tiotropium5 mg pool and one patient
in the placebo group (in both the placebo 5 mg pool and the placebo
2.5 mg pool) reported an asthma exacerbation; both of these required
hospitalisation, but treatment was not discontinued.Life-threatening SAEs occurred in ﬁve patients in the tiotropium
5 mg pool (0.4%; cerebral infarction [n ¼ 1]; hypotension, shock and
renal failure following hospitalisation for a non-life-threatening
asthma exacerbation [n ¼ 1]; acute respiratory failure and
asthma exacerbation [n ¼ 1]; anaphylactic reaction [n ¼ 1]; and
chemical poisoning [n ¼ 1]) and in one patient in the tiotropium
2.5 mg pool (0.1%; myocardial infarction); none of these life-
threatening SAEs was considered to be related to tiotropium
treatment. One patient in the placebo group experienced a life-
threatening SAE (0.1%; life-threatening asthma exacerbation; the
patient was enrolled in a trial investigating both tiotropium 5 mg
and 2.5 mg, and was therefore included in both the placebo 5 mg
pool and the placebo 2.5 mg pool) (Supplementary Table 2).
No deaths occurred during any of the seven trials.
3.3.2. AEs of special interest
Dry mouth, a common side effect associated with anticholin-
ergic therapies [14], was reported with a slightly higher frequency
in the tiotropium 5 mg pool versus placebo: tiotropium 5 mg, n ¼ 14
(1.0%); placebo 5 mg, n ¼ 7 (0.5%); tiotropium 2.5 mg, n ¼ 3 (0.4%);
placebo 2.5 mg, n ¼ 4 (0.5%). This was not classed as serious, nor did
it lead to treatment discontinuation, in any of the patients.
Treatment-related dry mouth AEs occurred with the following
patient frequencies: tiotropium 5 mg, n ¼ 11 (0.8%); placebo 5 mg,
n ¼ 5 (0.4%); tiotropium 2.5 mg, n ¼ 3 (0.4%); placebo 2.5 mg, n ¼ 3
(0.4%).
Table 6
Frequency of patients with treatment-related adverse events reported in 0.3% of patients in any treatment group (by primary system organ class and preferred term).
n (%) Tiotropium Respimat®
5 mg pool (N ¼ 1370)
Placebo Respimat® (tiotropium
Respimat® 5 mg pool)a (N ¼ 1317)
Tiotropium Respimat®
2.5 mg pool (N ¼ 787)
Placebo Respimat® (tiotropium
Respimat® 2.5 mg pool)a (N ¼ 735)
Patients with any treatment-
related AE
82 (6.0) 58 (4.4) 44 (5.6) 33 (4.5)
Respiratory, thoracic and
mediastinal disorders
32 (2.3) 28 (2.1) 11 (1.4) 13 (1.8)
Asthmab 12 (0.9) 13 (1.0) 3 (0.4) 5 (0.7)
Dysphonia 9 (0.7) 3 (0.2) 1 (0.1) 1 (0.1)
Cough 3 (0.2) 7 (0.5) 2 (0.3) 4 (0.5)
Dry throat 5 (0.4) 1 (0.1) 1 (0.1) 1 (0.1)
Oropharyngeal discomfort 1 (0.1) 0 3 (0.4) 0
Oropharyngeal pain 1 (0.1) 2 (0.2) 0 2 (0.3)
Gastrointestinal disorders 15 (1.1) 7 (0.5) 11 (1.4) 4 (0.5)
Dry mouth 11 (0.8) 5 (0.4) 3 (0.4) 3 (0.4)
Nausea 0 0 2 (0.3) 0
General disorders and
administration site
conditions
11 (0.8) 3 (0.2) 6 (0.8) 3 (0.4)
Thirst 9 (0.7) 3 (0.2) 3 (0.4) 3 (0.4)
Nervous system disorders 6 (0.4) 4 (0.3) 8 (1.0) 3 (0.4)
Headache 4 (0.3) 2 (0.2) 5 (0.6) 1 (0.1)
Investigations 9 (0.7) 6 (0.5) 5 (0.6) 4 (0.5)
Blood glucose abnormal 1 (0.1) 2 (0.2) 0 2 (0.3)
Gamma-glutamyltransferase
increased
3 (0.2) 0 2 (0.3) 0
Cardiac disorders 5 (0.4) 3 (0.2) 3 (0.4) 2 (0.3)
Palpitations 4 (0.3) 1 (0.1) 2 (0.3) 1 (0.1)
Treated set.
AE ¼ adverse event.
a Placebo Respimat® 5 mg pool: all seven trials; placebo Respimat® 2.5 mg pool: MezzoTinA-asthma®, GraziaTinA-asthma® and CadenTinA-asthma®.
b Represents asthma worsening or exacerbation.
Table 7
Frequency of patients with serious adverse events occurring in 2 patients in any treatment group (by primary system organ class and preferred term).
n (%) Tiotropium Respimat®
5 mg pool (N ¼ 1370)
Placebo Respimat® (tiotropium
Respimat® 5 mg pool)a (N ¼ 1317)
Tiotropium Respimat®
2.5 mg pool (N ¼ 787)
Placebo Respimat® (tiotropium
Respimat® 2.5 mg pool)a (N ¼ 735)
Patients with SAEs 55 (4.0) 65 (4.9) 16 (2.0) 24 (3.3)
Respiratory, thoracic and
mediastinal disorders
23 (1.7) 28 (2.1) 4 (0.5) 5 (0.7)
Asthmab 19 (1.4) 27 (2.1) 2 (0.3) 5 (0.7)
Infections and infestations 7 (0.5) 12 (0.9) 5 (0.6) 6 (0.8)
Pneumonia 2 (0.1) 2 (0.2) 2 (0.3) 0
Nervous system disorders 3 (0.2) 6 (0.5) 1 (0.1) 4 (0.5)
Cerebrovascular accident 1 (0.1) 2 (0.2) 0 2 (0.3)
Musculoskeletal and
connective tissue
disorders
4 (0.3) 4 (0.3) 2 (0.3) 1 (0.1)
Intervertebral disc
protrusion
1 (0.1) 2 (0.2) 0 0
Hepatobiliary disorders 2 (0.1) 3 (0.2) 0 0
Cholelithiasis 2 (0.1) 1 (0.1) 0 0
Vascular disorders 2 (0.1) 3 (0.2) 2 (0.3) 2 (0.3)
Hypertension 0 0 2 (0.3) 0
Treated set.
SAE ¼ serious adverse event.
a Placebo Respimat® 5 mg pool: all seven trials; placebo Respimat® 2.5 mg pool: MezzoTinA-asthma®, GraziaTinA-asthma® and CadenTinA-asthma®.
b Represents asthma worsening or exacerbation.
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frequently with tiotropium versus placebo in both pools: tio-
tropium 5 mg, n ¼ 4 (0.3%); placebo 5 mg, n ¼ 8 (0.6%); tiotropium
2.5 mg, n ¼ 1 (0.1%); placebo 2.5 mg, n ¼ 4 (0.5%). Urinary retention
AEs, also ‘class effect’ events, were not observed.
Ocular AEs were reported with similar frequency with tio-
tropium and placebo in both pools (tiotropium 5 mg, n ¼ 28 [2.0%];
placebo 5 mg, n¼ 24 [1.8%]; tiotropium 2.5 mg, n¼ 11 [1.4%]; placebo
2.5 mg, n ¼ 9 [1.2%]); the majority of ocular AEs were conjunctivitis.
Ocular discomfort, eye pain, eye swelling, blurred vision or events
related to glaucoma were each reported in 0.2% of patients.The number of patients with cardiac disorder AEs was low and
the frequency comparable in tiotropium and placebo groups in each
pool: tiotropium 5 mg, n ¼ 19 (1.4%); placebo 5 mg, n ¼ 19 (1.4%),
tiotropium 2.5 mg, n ¼ 11 (1.4%), placebo 2.5 mg, n ¼ 8 (1.1%). The
frequency of patients with treatment-related cardiac disorder AEs
was as follows: tiotropium 5 mg, n ¼ 5 (0.4%); placebo 5 mg pool,
n ¼ 3 (0.2%); tiotropium 2.5 mg, n ¼ 3 (0.4%); placebo 2.5 mg pool,
n ¼ 2 (0.3%). The proportion of patients with a cardiac history at
baseline (deﬁned as patients with at least one of the following
medical histories: myocardial infarction; cerebrovascular
accidents; cardiac arrhythmia; or heart failure New York Heart
Table 8
Summary of the frequency of patients with adverse events and serious adverse events, overall and in speciﬁc population subgroups.
n (%) Tiotropium Respimat® 5 mg
pool (N ¼ 1370)
Placebo Respimat® (tiotropium
Respimat® 5 mg pool)a
(N ¼ 1317)
Tiotropium Respimat® 2.5 mg
pool (N ¼ 787)
Placebo Respimat® (tiotropium
Respimat® 2.5 mg pool)a
(N ¼ 735)
Overall
Any AE 833 (60.8) 823 (62.5) 449 (57.1) 405 (55.1)
SAEs 55 (4.0) 65 (4.9) 16 (2.0) 24 (3.3)
Age group <65 years 65 years <65 years 65 years <65 years 65 years <65 years 65 years
n (% of N)b 1250 (91.2) 120 (8.8) 1186 (90.1) 131 (9.9) 746 (94.8) 41 (5.2) 699 (95.1) 36 (4.9)
Any AEc 751 (60.1) 82 (68.3) 723 (61.0) 100 (76.3) 427 (57.2) 22 (53.7) 381 (54.5) 24 (66.7)
SAEsc 45 (3.6) 10 (8.3) 51 (4.3) 14 (10.7) 16 (2.1) 0 21 (3.0) 3 (8.3)
Blood eosinophil count 0.6  109/L >0.6  109/L 0.6  109/L >0.6  109/L 0.6  109/L >0.6  109/L 0.6  109/L >0.6  109/L
n (% of N)b 1072 (78.2) 281 (20.5) 1038 (78.8) 262 (19.9) 615 (78.1) 170 (21.6) 580 (78.9) 154 (21.0)
Any AEc 641 (59.8) 181 (64.4) 635 (61.2) 175 (66.8) 338 (55.0) 110 (64.7) 316 (54.5) 89 (57.8)
SAEsc 41 (3.8) 12 (4.3) 50 (4.8) 14 (5.3) 12 (2.0) 4 (2.4) 18 (3.1) 6 (3.9)
LTRA use at baseline þ LTRA  LTRA þ LTRA  LTRA þ LTRA  LTRA þ LTRA  LTRA
n (% of N)b 166 (12.1) 1204 (87.9) 166 (12.6) 1151 (87.4) 84 (10.7) 703 (89.3) 58 (7.9) 677 (92.1)
Any AEc 126 (75.9) 707 (58.7) 131 (78.9) 692 (60.1) 62 (73.8) 387 (55.0) 36 (62.1) 369 (54.5)
SAEsc 12 (7.2) 43 (3.6) 15 (9.0) 50 (4.3) 2 (2.4) 14 (2.0) 3 (5.2) 21 (3.1)
Treated set.
AE ¼ adverse event. LTRA ¼ leukotriene receptor antagonist.
a Placebo Respimat® 5 mg pool: all seven trials; placebo Respimat® 2.5 mg pool: MezzoTinA-asthma®, GraziaTinA-asthma® and CadenTinA-asthma®.
b Percentages calculated using total number of patients per treatment pool as the denominator.
c Percentages calculated using total number of patients per subgroup per treatment as the denominator.
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patients were not excluded if they developed cardiac AEs during
the trial.
The most common cardiac disorder AEs overall were palpita-
tions and tachycardia, and none was reported in more than 0.5% of
patients in any treatment arm (Supplementary Table 3).
Serious cardiac disorder AEs occurred in two patients (0.1%) in
the tiotropium 5 mg pool (supraventricular arrhythmia, coronary
artery occlusion, coronary artery stenosis and ventricular tachy-
cardia in one patient; atrial ﬁbrillation in one patient) and in two
patients (0.3%) in the tiotropium 2.5 mg pool (atrial ﬁbrillation and
myocardial infarction). One patient (0.1%) common to both placebo
pools (the patient was enrolled in a trial investigating both tio-
tropium 5 mg and 2.5 mg) experienced two cardiac disorder SAEs
(acute myocardial infarction and coronary artery disease). None of
the serious cardiac disorder AEs was considered treatment-related.
There were no patients with fatal major adverse cardiovascular
events (deﬁned in Supplementary Table 4); non-fatal major adverse
cardiovascular events were reported in nine patients overall: tio-
tropium 5 mg pool, n ¼ 4 (0.3%); placebo 5 mg pool, n ¼ 4, (0.3%);
tiotropium 2.5 mg pool, n ¼ 1 (0.1%); placebo 2.5 mg pool, n ¼ 4
(0.5%).
3.3.3. Safety in population subgroups
Table 8 presents a summary of AE and SAE frequencies in patient
subgroups across which the frequency of AEs is known to vary; for
example, the incidence of AEs tends to be higher in elderly patients.
Accordingly, we include ﬁndings from three subgroups of interest:
age < and 65 years; high versus low blood eosinophil count, and
with and without leukotriene receptor antagonist (LTRA) use at
baseline.
In the overall pooled analysis and in patients <65 years of age,
the frequencies of patients with AEs and SAEs were comparable
between treatment groups, while in patients65 years of age these
frequencies were higher with placebo thanwith tiotropium in both
pools (Table 8). Such differences should be treated with some
caution because of the small number of patients in the older age
group (n ¼ 36e131).
As in the overall analysis, the frequencies of patients with AEsand SAEs were generally comparable between treatment groups in
the low eosinophil (0.6  109/L) and high eosinophil (>0.6  109/
L) subgroups in both pools (Table 8), although in the high eosino-
phil subgroup therewas a slightly higher frequency of patients with
AEs in the tiotropium 2.5 mg pool (64.7%) compared with the cor-
responding placebo pool (57.8%).
In the subgroups with and without LTRA use at baseline, the
frequencies of patients with AEs and SAEs were generally compa-
rable between treatment groups, as in the overall analysis (Table 8).
An exception to this was the higher frequency of patients with AEs
in the tiotropium 2.5 mg pool compared with the corresponding
placebo pool in the LTRA use subgroup.
Patients with a history of renal or urinary tract diseases formed a
small proportion of the pooled analysis data set (tiotropium 5 mg,
n ¼ 25, 1.8%; placebo 5 mg, n ¼ 27, 2.1%; tiotropium 2.5 mg, n ¼ 20,
2.5%; placebo 2.5 mg, n ¼ 13, 1.8%). Renal and urinary disorder AEs
were reported in similar proportions of patients across treatment
groups in each pool: tiotropium 5 mg, n ¼ 7, 0.5%; placebo 5 mg,
n ¼ 10, 0.8%; tiotropium 2.5 mg, n ¼ 4, 0.5%; placebo 2.5 mg, n ¼ 2,
0.3%. Renal failure or acute renal failure was reported as an SAE in
one patient in the tiotropium 5 mg pool and in one patient in the
placebo 5 mg pool.
4. Discussion
In this pooled analysis of data from 3474 patients with symp-
tomatic asthmawho received tiotropium or placebo as add-on to at
least ICS maintenance therapy, the frequencies of patients report-
ing AEs, SAEs and treatment-related AEs were comparable between
tiotropium and placebo treatment groups, and there were no
deaths. Dry mouth, an AE of special interest because of its known
association with anticholinergic therapies, was reported at a
slightly higher frequency with tiotropium than with placebo, but
was less frequent than that reported in studies of patients with
COPD [15]. Importantly, dry mouth was not described as serious,
nor did it lead to discontinuation of the study medication, in any of
the asthma patients in the analysis.
The frequencies of patients with cardiac disorder AEs and SAEs
were low overall and balanced between tiotropium and placebo
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population subgroups deﬁned by age (< and 65 years), blood
eosinophil count and LTRA use at baseline, the frequencies of
patients with AEs and SAEs were generally comparable between
treatment groups.
Our ﬁndings in patients with symptomatic asthma are consis-
tent with the safety signals observed with tiotropium in patients
with COPD [15,16]. In 2014, previous concerns in COPD (based on
pooled post hoc analyses and meta-analyses) that there may be
have been an increased risk of death with tiotropium Respimat®
were convincingly disproven in the large-scale (17,135 patients)
TIOSPIR study [15]. It is evident that tiotropium is well tolerated in
both conditions, and, indeed, as we have highlighted, there have
been no deaths in any of the trials that have investigated tiotropium
Respimat® for the treatment of asthma. The fact that patients with
asthma tend to be younger and have fewer co-morbidities than
patients with COPD may explain the lower overall rate of AEs and
SAEs in the current analysis.
A limitation of our pooled analysis includes the different du-
rations of the seven included trials and that none was longer than
52 weeks. Although the pool included three trials of between 48
and 52 weeks’ duration, these contributed a relatively small pro-
portion of patients to the overall pool, and the remaining trials
were between 12 and 24 weeks’ duration. While the primary
objective of CadenTinA-asthma® was to evaluate the safety of
tiotropium over 52 weeks, none of the trials was powered indi-
vidually to assess safety as a primary end point. There is also a
degree of limitation in our ﬁndings in that all participants were
screened for, and treated in, randomised controlled trials, rather
than in a ‘real-life’ setting. Nevertheless, in all of the trials included
in our analysis all patients were required to have symptomatic
asthma at entry, and tiotropium or placebo were administered on
top of a wide range of patients’ normal background therapy (ICS
with or without other controller medication). We therefore believe
that our pooled trial population presented here is as representative
of the ‘true’ asthma population as can be achieved in a randomised
clinical trial setting.
The major advantage of this analysis is that all trials included in
the pool were placebo-controlled and therefore provide the most
valid comparison for assessing adverse reactions associated with
tiotropium use. An additional strength is that all pooled trials were
sourced from one clinical trial programme, offering a high degree of
consistency in study design while also including a relatively wide
variety of asthma severities through differences in inclusion and
exclusion criteria. Furthermore, because of their add-on design, all
patients continued to receive their usual background therapies,
allowing investigation of tiotropium therapy in varied settings of
concurrent medications. A further strength is that the patient
sample was recruited from various populations and geographic
regions, and includes a high proportion of Asian patients.
5. Conclusions
In summary, once-daily tiotropium Respimat® as add-on to
maintenance treatment in adult patients with symptomatic asthma
at different treatment steps, including ICS, demonstrated a safety
and tolerability proﬁle comparable with that of placebo.
Role of the funding source
This work was supported by Boehringer Ingelheim. ME, LZP and
PMZ are all employees of Boehringer Ingelheim and were involved
in the study design, analysis, interpretation and writing of themanuscript, and in the decision to submit the article for
publication.
Acknowledgements
The authors take full responsibility for the scope, direction,
content of and editorial decisions relating to the manuscript, were
involved at all stages of development and have approved the
submitted manuscript. This work was supported ﬁnancially by
Boehringer Ingelheim. Boehringer Ingelheim was not involved in
the development of this publication and reviewed the ﬁnal
version for scientiﬁc accuracy only. Medical writing assistance, in
the form of the preparation and revision of the manuscript, was
supported ﬁnancially by Boehringer Ingelheim and provided by
Laura Gibbons, PhD, at Complete HealthVizion under the authors’
conceptual direction and based on feedback from the authors.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.rmed.2016.07.001.
References
[1] Global Initiative for Asthma, Global Strategy for Asthma Management and
Prevention, 2015. Updated 2015, http://ginasthma.org/wp[HYPHEN]content/
uploads/2016/01 (accessed 10.03.16).
[2] E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J.H. Clark, R.A. Pauwels,
et al., Can guideline-deﬁned asthma control be achieved? The Gaining Optimal
Asthma ControL study, Am. J. Respir. Crit. Care Med. 170 (8) (2004) 836e844,
http://dx.doi.org/10.1164/rccm.200401-033OC.
[3] M.R. Partridge, R.W. Dal Negro, D. Olivieri, Understanding patients with
asthma and COPD: insights from a European study, Prim. Care Respir. J. 20 (3)
(2011) 315e323.
[4] P. Demoly, P. Paggiaro, V. Plaza, S.C. Bolge, H. Kannan, B. Sohier, et al., Prev-
alence of asthma control among adults in France, Germany, Italy, Spain and
the UK, Eur. Respir. Rev. 18 (112) (2009) 105e112.
[5] H.A.M. Kerstjens, B. Disse, W. Schr€oder-Babo, T.A. Bantje, M. Gahlemann,
R. Sigmund, et al., Tiotropium improves lung function in patients with severe
uncontrolled asthma: a randomized controlled trial, J. Allergy Clin. Immunol.
128 (2) (2011) 308e314, http://dx.doi.org/10.1016/j.jaci.2011.04.039.
[6] E.D. Bateman, O. Kornmann, P. Schmidt, A. Pivovarova, M. Engel, L.M. Fabbri,
Tiotropium is noninferior to salmeterol in maintaining improved lung func-
tion in B16-Arg/Arg patients with asthma, J. Allergy Clin. Immunol. 128 (2)
(2011) 315e322, http://dx.doi.org/10.1016/j.jaci.2011.06.004.
[7] K.M. Beeh, P. Moroni-Zentgraf, O. Ablinger, Z. Hollaenderova, A. Unseld,
M. Engel, et al., Tiotropium Respimat® in asthma: a double-blind, randomised,
dose-ranging study in adult patients with moderate asthma, Respir. Res. 15
(2014) 61, http://dx.doi.org/10.1186/1465-9921-15-61.
[8] W. Timmer, P. Moroni-Zentgraf, P. Cornelissen, A. Unseld, E. Pizzichini, R. Buhl,
Once-daily tiotropium Respimat® 5 mg is an efﬁcacious 24-hour bronchodi-
lator in adults with symptomatic asthma, Respir. Med. 109 (3) (2015)
329e338, http://dx.doi.org/10.1016/j.rmed.2014.12.005.
[9] H.A.M. Kerstjens, M. Engel, R. Dahl, P. Paggiaro, E. Beck, M. Vandewalker, et al.,
Tiotropium in asthma poorly controlled with standard combination therapy,
N. Engl. J. Med. 367 (13) (2012) 1198e1207, http://dx.doi.org/10.1056/
NEJMoa1208606.
[10] H.A.M. Kerstjens, T.B. Casale, E.R. Bleecker, E.O. Meltzer, E. Pizzichini,
O. Schmidt, et al., Tiotropium or salmeterol as add-on therapy to inhaled
corticosteroids for patients with moderate symptomatic asthma: two repli-
cate, double-blind, placebo-controlled, parallel-group, active-comparator,
randomised trials, Lancet Respir. Med. 3 (5) (2015) 367e376, http://
dx.doi.org/10.1016/S2213-2600(15)00031-4.
[11] K. Ohta, M. Ichinose, Y. Tohda, M. Engel, P. Moroni-Zentgraf, S. Kunimitsu, et
al., Long-term once-daily tiotropium Respimat® is well tolerated and main-
tains efﬁcacy over 52 weeks in patients with symptomatic asthma in Japan: a
randomised, placebo-controlled study, PLoS One 10 (4) (2015) e0124109.
[12] P. Paggiaro, D.M. Halpin, R. Buhl, M. Engel, V.B. Zubek, Z. Blahova, et al., The
effect of tiotropium in symptomatic asthma despite low- to medium-dose
inhaled corticosteroids: a randomized controlled trial, J. Allergy Clin. Immu-
nol. Pract. 4 (2016) 104e113.e2, http://dx.doi.org/10.1016/j.jaip.2015.08.017.
[13] K.M. Beeh, A.M. Kirsten, D. Dusser, A. Sharma, P. Cornelissen, R. Sigmund, et
al., Pharmacodynamics and pharmacokinetics following once-daily and twice-
daily dosing of tiotropium Respimat® in asthma using standardized sample-
contamination avoidance, J. Aerosol Med. Pulm. Drug Deliv. (2016), http://
dx.doi.org/10.1089/jamp.2015.1260 [Epub ahead of print].
R. Dahl et al. / Respiratory Medicine 118 (2016) 102e111 111[14] B.C. Moulton, A.D. Fryer, Muscarinic receptor antagonists, from folklore to
pharmacology; ﬁnding drugs that actually work in asthma and COPD, Br. J.
Pharmacol. 163 (1) (2011) 44e52.
[15] Boehringer Ingelheim Pharmaceuticals, Inc., SPIRIVA® RESPIMAT® (tiotropium
bromide) inhalation spray, for oral inhalation, 2015. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/
spirivarespimat.pdf (accessed 05.11.15).
[16] R.A. Wise, Tiotropium and the risk of death in COPD, N. Engl. J. Med. 370 (5)
(2014) 482.
